Biotech trend — Disruption score: 8.5/10
The engineered IS621 recombinase/bridge RNA system enables scarless, site-specific insertion of large DNA fragments in human cells at up to 27.75% efficiency — a major advance over current CRISPR-based approaches that struggle with large cargo integration. Demonstrated CAR-T and hemophilia B Factor IX applications signal near-term therapeutic relevance. This programmable, non-viral integration platform could displace existing gene-editing toolkits, directly benefiting cell therapy and rare disease gene therapy developers.
Paradigm Shift detected
Commercially Viable
Loading…